Regulators increasingly emphasise total process understanding from development to commercial scale. With 75% of FDA rejections tied to CMC shortcomings, LC-MS-based HCP impurity analysis is key to a regulatory-ready, data-driven purification strategy.
Thomas Kofoed, CEO and Co-Founder, Alphalyse